Global Leukemia Therapeutics Market, By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Others), By Gender, By Age Groups, By Diagnosis, By Treatment, By Drugs, By Route of Administration, By Region, Competition Forecast & Opportunities, 2026

Description Table of
Contents Companies Mentioned

FEATURED COMPANIES

AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Gilead Sciences Inc.
iCell Gene therapeutics
MORE

The Global Leukemia Therapeutics Market was valued USD18584.23 Million in 2020 and is expected to grow at a CAGR of 7.47% during the forecast period. The Global Leukemia Therapeutics Market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Supportive government initiatives and policies for promoting cancer awareness are anticipated to fuel the market growth until 2026.

Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.

The Global Leukemia Therapeutics Market can be segmented based on type, gender, age groups, diagnosis, treatment, drugs, route of administration, company and region. Based on type, the market can be bifurcated into chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and others. The chronic lymphocytic leukemia segment led the market in 2020 with share of 34.52%. This can be accredited to the rising geriatric population and increasing funding for research and the development of new cancer therapies. The male and geriatric population are mostly affected by leukemia. The most common diagnosis method of this type of cancer is biopsy whereas, imaging is expected to grow in the near future owing to the improvement and adoption of technology across the globe. Amongst the drug segment, tyrosine kinase inhibitors dominated the Global Leukemia Therapeutics Market owing to their greater efficacy and fewer side effects as compared to the rest. Most of the treatments and drugs are administered via injections via intravenous, subcutaneous, intramuscular and intrathecal modes.

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market with one-third share during the forecast period. This can be attributed to the presence of a large geriatric population base. Besides, the presence of key players in the region is further expected to propel the market over 2026.

Major players operating in the Global Leukemia Therapeutics Market include Novartis AG, AbbVie Inc., Roche Holding AG, Amgen Inc., AstraZeneca PLC, Pfizer Inc., Merck & Company Inc., Eli Lilly and Company Ltd., Bristol-Myers Squibb Company, Gilead Sciences Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Stemline Therapeutics Inc., iCell Gene Therapeutics, Otsuka Holdings Company Ltd. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in September 2020, Gilead Sciences Inc. completed the acquisition of Immunomedics Inc., which was one of the biggest acquisition in 2020.

Years considered for this report:

Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022- 2026

Objective of the Study:

To analyze historical growth in market size of the Global Leukemia Therapeutics Market from 2016 to 2020.
. To estimate and forecast the market size of the Global Leukemia Therapeutics Market from 2021 to 2026 and growth rate until 2026.
To classify and forecast the Global Leukemia Therapeutics Market based on factor, severity, blood cell, age groups, gender, treatment, diagnosis, route of administration, drugs, company and regional distribution.
To identify drivers and challenges for the Global Leukemia Therapeutics Market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Leukemia Therapeutics Market.
To identify and analyze the profiles of leading players operating in the Global Leukemia Therapeutics Market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The publisher analyzed the manufacturers, distribution channels and presence of all major players across the globe.

The publisher calculated the market size of the Global Leukemia Therapeutics Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:

Leukemia drugs manufacturers, suppliers, distributors and other stakeholders
Government bodies such as regulating authorities and policy makers
Organizations, forums and alliances related to leukemia therapeutics
Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:

In this report, the Global Leukemia Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Leukemia Therapeutics Market, By Type:

Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Others

Global Leukemia Therapeutics Market, By Gender:

Male
Female

Global Leukemia Therapeutics Market, By Age Groups:

0-15
15-30
30-50
50+

Global Leukemia Therapeutics Market, By Diagnosis:

Blood test
Biopsy
Physical Exam
Imaging

Global Leukemia Therapeutics Market, By Treatment:

Chemotherapy
Stem Cell Transplantation
Immunotherapy
Targeted Therapy
Others

Global Leukemia Therapeutics Market, By Drugs:

Tyrosine Kinase Inhibitors
Antimetabolites
Hormones (Corticosteroids)
Monoclonal Antibodies
Others

Global Leukemia Therapeutics Market, By Route of Administration:

Oral
Parenteral

Global Leukemia Therapeutics Market, By Region:

North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Asia-Pacific
China
Japan
India
South Korea
Australia
Middle East & Africa
South Africa
Saudi Arabia
UAE
South America
Brazil
Argentina
Colombia

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Leukemia Therapeutics Market.

Available Customizations:
With the given market data, the publisher offers customizations according to a client’s specific needs.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Gilead Sciences Inc.
iCell Gene therapeutics
MORE

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Leukemia Therapeutics Market4. Executive Summary

5. Voice of Customer

5.1. Brand Awareness
5.2. Factors driving Global Leukemic Therapeutics Market
5.3. Unmet Needs and Challenges

6. Global Leukemia Therapeutics Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others)
6.2.2. By Gender (Male, Female)
6.2.3. By Age Groups (0-15, 15-30, 30-50, 50+)
6.2.4. By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging)
6.2.5. By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others)
6.2.6. By Drugs (Antimetabolites, Hormones (Corticosteroids), Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others)
6.2.7. By Route of Administration (Oral, Parenteral)
6.2.8. By Company (2020)
6.2.9. By Region

7. North America Leukemia Therapeutics Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Diagnosis
7.2.3. By Treatment
7.2.4. By Drugs
7.2.5. By Route of Administration
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Leukemia Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Diagnosis
7.3.1.2.3. By Treatment
7.3.1.2.4. By Drugs
7.3.1.2.5. By Route of Administration
7.3.2. Canada Leukemia Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By Treatment
7.3.2.2.4. By Drugs
7.3.2.2.5. By Route of Administration
7.3.3. Mexico Leukemia Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By Treatment
7.3.3.2.4. By Drugs
7.3.3.2.5. By Route of Administration

8. Europe Leukemia Therapeutics Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Diagnosis
8.2.3. By Treatment
8.2.4. By Drugs
8.2.5. By Route of Administration
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Leukemia Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Diagnosis
8.3.1.2.3. By Treatment
8.3.1.2.4. By Drugs
8.3.1.2.5. By Route of Administration
8.3.2. France Leukemia Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By Treatment
8.3.2.2.4. By Drugs
8.3.2.2.5. By Route of Administration
8.3.3. United Kingdom Leukemia Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By Treatment
8.3.3.2.4. By Drugs
8.3.3.2.5. By Route of Administration
8.3.4. Italy Leukemia Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By Treatment
8.3.4.2.4. By Drugs
8.3.4.2.5. By Route of Administration
8.3.5. Spain Leukemia Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By Treatment
8.3.5.2.4. By Drugs
8.3.5.2.5. By Route of Administration

9. Asia-Pacific Leukemia Therapeutics Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Diagnosis
9.2.3. By Treatment
9.2.4. By Drugs
9.2.5. By Route of Administration
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Leukemia Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Diagnosis
9.3.1.2.3. By Treatment
9.3.1.2.4. By Drugs
9.3.1.2.5. By Route of Administration
9.3.2. India Leukemia Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Treatment
9.3.2.2.4. By Drugs
9.3.2.2.5. By Route of Administration
9.3.3. Japan Leukemia Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Diagnosis
9.3.3.2.3. By Treatment
9.3.3.2.4. By Drugs
9.3.3.2.5. By Route of Administration
9.3.4. South Korea Leukemia Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Diagnosis
9.3.4.2.3. By Treatment
9.3.4.2.4. By Drugs
9.3.4.2.5. By Route of Administration
9.3.5. Australia Leukemia Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Diagnosis
9.3.5.2.3. By Treatment
9.3.5.2.4. By Drugs
9.3.5.2.5. By Route of Administration

10. South America Leukemia Therapeutics Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Diagnosis
10.2.3. By Treatment
10.2.4. By Drugs
10.2.5. By Route of Administration
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Leukemia Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Diagnosis
10.3.1.2.3. By Treatment
10.3.1.2.4. By Drugs
10.3.1.2.5. By Route of Administration
10.3.2. Argentina Leukemia Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Diagnosis
10.3.2.2.3. By Treatment
10.3.2.2.4. By Drugs
10.3.2.2.5. By Route of Administration
10.3.3. Colombia Leukemia Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Diagnosis
10.3.3.2.3. By Treatment
10.3.3.2.4. By Drugs
10.3.3.2.5. By Route of Administration

11. Middle East and Africa Leukemia Therapeutics Market Outlook

11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Diagnosis
11.2.3. By Treatment
11.2.4. By Drugs
11.2.5. By Route of Administration
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Leukemia Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Diagnosis
11.3.1.2.3. By Treatment
11.3.1.2.4. By Drugs
11.3.1.2.5. By Route of Administration
11.3.2. Saudi Arabia Leukemia Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Diagnosis
11.3.2.2.3. By Treatment
11.3.2.2.4. By Drugs
11.3.2.2.5. By Route of Administration
11.3.3. UAE Leukemia Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Diagnosis
11.3.3.2.3. By Treatment
11.3.3.2.4. By Drugs
11.3.3.2.5. By Route of Administration

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments14. Clinical Trial Analysis

15. Competitive Landscape

15.1. Competition Outlook
15.2. Players Profiled (Leading Companies)
15.2.1. Novartis AG
15.2.2. AbbVie Inc.
15.2.3. Roche Holding AG
15.2.4. Amgen Inc.
15.2.5. AstraZeneca PLC
15.2.6. Pfizer Inc.
15.2.7. Merck & Company Inc.
15.2.8. Eli Lilly and Company Ltd.
15.2.9. Bristol-Myers Squibb Company
15.2.10. Gilead Sciences Inc.
15.2.11. Astellas Pharma Inc.
15.2.12. Takeda Pharmaceutical Company Ltd.
15.2.13. Stemline Therapeutics Inc.
15.2.14. iCell Gene therapeutics
15.2.15. Otsuka Holdings Company Ltd.

16. Strategic Recommendations17. About the Publisher & Disclaimer

List of Figures

Figure 1: Global Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 2: Global Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 3: Global Leukemia Therapeutics Market Share, By Gender, 2016-2026F
Figure 4: Global Leukemia Therapeutics Market Share, By Age Groups, 2016-2026F
Figure 5: Global Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 6: Global Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 7: Global Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 8: Global Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 9: Global Leukemia Therapeutics Market, Market Map, By Region, By Value, 2016-2026F
Figure 10: North America Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 11: North America Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 12: North America Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 13: North America Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 14: North America Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 15: North America Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 16: North America Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 17: United States Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 18: United States Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 19: United States Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 20: United States Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 21: United States Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 22: United States Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 23: Canada Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 24: Canada Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 25: Canada Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 26: Canada Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 27: Canada Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 28: Canada Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 29: Mexico Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 30: Mexico Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 31: Mexico Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 32: Mexico Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 33: Mexico Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 34: Mexico Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 35: Europe Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 36: Europe Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 37: Europe Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 38: Europe Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 39: Europe Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 40: Europe Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 41: Europe Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 42: Germany Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 43: Germany Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 44: Germany Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 45: Germany Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 46: Germany Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 47: Germany Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 48: France Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 49: France Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 50: France Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 51: France Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 52: France Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 53: France Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 54: United Kingdom Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 55: United Kingdom Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 56: United Kingdom Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 57: United Kingdom Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 58: United Kingdom Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 59: United Kingdom Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 60: Italy Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 61: Italy Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 62: Italy Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 63: Italy Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 64: Italy Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 65: Italy Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 66: Spain Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 67: Spain Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 68: Spain Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 69: Spain Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 70: Spain Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 71: Spain Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 72: Asia-Pacific Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 73: Asia-Pacific Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 74: Asia-Pacific Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 75: Asia-Pacific Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 76: Asia-Pacific Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 77: Asia-Pacific Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 78: Asia-Pacific Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 79: China Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 80: China Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 81: China Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 82: China Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 83: China Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 84: China Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 85: India Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 86: India Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 87: India Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 88: India Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 89: India Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 90: India Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 91: Japan Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 92: Japan Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 93: Japan Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 94: Japan Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 95: Japan Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 96: Japan Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 97: South Korea Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 98: South Korea Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 99: South Korea Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 100: South Korea Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 101: South Korea Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 102: South Korea Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 103: Australia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 104: Australia Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 105: Australia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 106: Australia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 107: Australia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 108: Australia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 109: South America Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 110: South America Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 111: South America Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 112: South America Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 113: South America Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 114: South America Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 115: South America Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 116: Brazil Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 117: Brazil Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 118: Brazil Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 119: Brazil Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 120: Brazil Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 121: Brazil Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 122: Argentina Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 123: Argentina Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 124: Argentina Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 125: Argentina Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 126: Argentina Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 127: Argentina Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 128: Colombia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 129: Colombia Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 130: Colombia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 131: Colombia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 132: Colombia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 133: Colombia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 134: Middle East and Africa Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 135: Middle East and Africa Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 136: Middle East and Africa Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 137: Middle East and Africa Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 138: Middle East and Africa Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 139: Middle East and Africa Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 140: Middle East and Africa Leukemia Therapeutics Market Share, By Country, 2016-2026F
Figure 141: South Africa Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 142: South Africa Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 143: South Africa Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 144: South Africa Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 145: South Africa Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 146: South Africa Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 147: Saudi Arabia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 148: Saudi Arabia Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 149: Saudi Arabia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 150: Saudi Arabia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 151: Saudi Arabia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 152: Saudi Arabia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
Figure 153: UAE Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 154: UAE Leukemia Therapeutics Market Share, By Type, 2016-2026F
Figure 155: UAE Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
Figure 156: UAE Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
Figure 157: UAE Leukemia Therapeutics Market Share, By Drug, 2016-2026F
Figure 158: UAE Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F

Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

Novartis AG
AbbVie Inc.
Roche Holding AG
Amgen Inc.
AstraZeneca PLC
Pfizer Inc.
Merck & Company Inc.
Eli Lilly and Company Ltd.
Bristol-Myers Squibb Company
Gilead Sciences Inc.
Astellas Pharma Inc.
Takeda Pharmaceutical Company Ltd.
Stemline Therapeutics Inc.
iCell Gene therapeutics
Otsuka Holdings Company Ltd.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

FEATURED COMPANIES

RELATED TAGS

RELATED PRODUCTS

The Pharmaceutical Industry in South Africa 2022

Chronic Lymphocytic Leukemia Therapeutics Market Research Report by Treatment Type, Route of Administration, End-Users, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Hairy Cell Leukemia (Oncology) - Drugs In Development, 2021

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) - Drugs in Development, 2021